Celgene Corp (CELG)

CELG (NASDAQ:Drugs) EQUITY
$115.35
neg -4.70
-3.90%
Today's Range: 114.97 - 119.28 | CELG Avg Daily Volume: 5,386,100
Last Update: 03/31/15 - 3:59 PM EDT
Volume: 11,313,277
YTD Performance: 7.29%
Open: $118.88
Previous Close: $120.02
52 Week Range: $66.85 - $129.06
Oustanding Shares: 800,590,656
Market Cap: 95,014,099,054
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 14 15 14 16
Moderate Buy 1 1 1 1
Hold 4 4 4 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.47 1.45 1.47 1.26
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 49.66
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
49.66 49.60 27.35
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
5.71% 72.33% 209.65%
GROWTH 12 Mo 3 Yr CAGR
Revenue 18.10 0.58 0.16
Net Income 37.90 0.52 0.15
EPS 42.00 0.72 0.20
Earnings for CELG:
EBITDA 2.94B
Revenue 7.67B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.90 $1.03 $4.32 $6.09
Number of Analysts 3 3 3 3
High Estimate $0.93 $1.12 $4.47 $7.21
Low Estimate $0.87 $0.98 $4.23 $5.45
Prior Year $0.73 $0.80 $3.36 $4.32
Growth Rate (Year over Year) 23.29% 29.17% 28.57% 40.97%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Where are Celgene, Isis and CVS heading?
Here are healthcare stocks of all shares and sizes with strong charts.
Three stocks were ripe for buying after the pullback.
An answer to those asking me what's worth buying.
If there is no catalyst, I'd join those who sell on a bounce.
It takes a village of positive reports to sustain market.
Own them, or take something off the table?
I really like the stocks. But I also like making money on stocks.
Market backtracks on skepticism over biotechs.
Sector could regain its leadership role.

Columnist Conversations

Market ends the month and the quarter on a down note. Indices are largely flat for 2015, in the weakest openi...
Micron is holding a key support zone ahead of Thursday afternoon's Q2 earnings report. Today the stock i...
All of the action in Apple Inc. (AAPL) since its February 24 all-time high at 133.60 has the right look of a s...
Shares of the Walt Disney Company (DIS) have been moving higher over the last two months in a broadening forma...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.